Zydus Cadila receives tentative approval from USFDA for Pimavanserin Capsules

Zydus Cadila's U.S. subsidiary Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the USFDA to market Pimavanserin Capsules in the strength of 34 mg (USRLD: Nuplazid® Capsules). Pimavanserin is an atypical antipsychotic and is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

The drug will be manufactured at the group's formulation manufacturing facility at SEZ Ahmedabad. The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 479.30 as compared to the previous close of Rs. 469.45. The total number of shares traded during the day was 266146 in over 6533 trades.

The stock hit an intraday high of Rs. 483.00 and intraday low of 468.15. The net turnover during the day was Rs. 126817145.00.

Source : Equity Bulls

Keywords

CadilaHealthcare INE010B01027 CADILAHC Pharmaceuticals TentativeApproval USFDA Pimavanserin Nuplazid